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Abstract
Mesenchymal stem/stromal cells (MSC) are currently the best candidate therapeutic cells for regenerative medicine related to osteoarticular,
muscular, vascular and inflammatory diseases, although these cells remain heterogeneous and necessitate a better biological characterization.
We and others recently described that MSC originate from two types of perivascular cells, namely pericytes and adventitial cells and contain the
in situ counterpart of MSC in developing and adult human organs, which can be prospectively purified using well defined cell surface markers.
Pericytes encircle endothelial cells of capillaries and microvessels and express the adhesion molecule CD146 and the PDGFRb, but lack endo-
thelial and haematopoietic markers such as CD34, CD31, vWF (von Willebrand factor), the ligand for Ulex europaeus 1 (UEA1) and CD45
respectively. The proteoglycan NG2 is a pericyte marker exclusively associated with the arterial system. Besides its expression in smooth mus-
cle cells, smooth muscle actin (aSMA) is also detected in subsets of pericytes. Adventitial cells surround the largest vessels and, opposite to
pericytes, are not closely associated to endothelial cells. Adventitial cells express CD34 and lack aSMA and all endothelial and haematopoietic
cell markers, as for pericytes. Altogether, pericytes and adventitial perivascular cells express in situ and in culture markers of MSC and display
capacities to differentiate towards osteogenic, adipogenic and chondrogenic cell lineages. Importantly, adventitial cells can differentiate into
pericyte-like cells under inductive conditions in vitro. Altogether, using purified perivascular cells instead of MSC may bring higher benefits to
regenerative medicine, including the possibility, for the first time, to use these cells uncultured.
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Introduction
Despite an ever developing interest in the promising properties of
mesenchymal stem cells (MSC), the true nature and identity of
these cells has always been elusive. MSC, which were originally
extracted from adult bone marrow [1], are now obtained from
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many tissues and are defined by their ability to adhere to plastic in
culture, expression of a set of surface markers and capacity to dif-
ferentiate into mesodermal cell lineages. Yet, these cells remain
heterogeneous and not well characterized [2–4]. Is the heterogene-
ity of cultured MSC reflective of the existence of distinct MSC pro-
genitors in situ? We have hypothesized that because of their
presence in virtually all organs, blood vessels represent a reservoir
of these mesodermal stem cells. The presence of related progeni-
tors, named mesoangioblasts because of their ability to differentiate
into endothelial cells and other mesodermal lineages, has been
already demonstrated in the embryonic dorsal aorta [5, 6]. More-
over, haematopoietic stem cells are generated from a hemogenic
endothelium in the embryonic aortic wall [7]. Finally, the identifica-
tion of mesodermal progenitors in the tunica adventitia suggests
that the outmost layer of blood vessels also contributes to tissue
homeostasis and repair [8]. These results led us to further investi-
gate the presence of MSC within the vascular wall in various devel-
oping and adult human organs. Small blood vessels are formed by
endothelial and mural cells. Charles Marie Benjamin Rouget
described for the first time mural cells of capillaries as ‘non-pig-
mented adventitial cells’ or ‘intramural pericytes’, very closely asso-
ciated with the endothelium and extending numerous ramified
protoplasmic processes [9]. His name was given to these cells—
Rouget cells—until 1923, when Zimmermann renamed them peri-
cytes, described as being mainly associated with vessel contractile
function [10]. Electron microscopy described pericytes as cellular
structures encapsulated under the basal membrane of microvessels
(diameter: 10–100 lm) and capillaries (diameter <10 lm) where
they form a single layer around and in close contact with the endo-
thelium. In this respect, the presence of pericytes in vessels devoid
of basement membrane is by definition not expected, as for exam-
ple in hepatic sinusoids [11]. Thus, pericytes are clearly distin-
guishable from other perivascular cells, smooth muscle cells and
adventitial cells, found around larger blood vessels and outside the
basal membrane. Pericyte morphology is also different, these being
large, stellate cells. In situ, pericytic cytoplasmic protuberances run
parallels to the longitudinal axis of capillaries, but circular around
microvessels [12]. Other than pericytes, adventitial cells represent
another perivascular cell type. The wall of all blood vessels, but
capillaries, is constituted by three layers named tunica intima,
tunica media and tunica adventitia. The tunica adventitia is the out-
most layer of the vascular wall, originally described as an unorga-
nized structure composed by fibroblasts, collagen and nerves
playing a role in maintaining vessel structural integrity. More
recently, a number of studies have reported a dynamic role for the
tunica adventitia in vascular remodelling [8, 13–16] inflammation
and immune response [17–20]. Although pericytes and adventitial
perivascular cells have been described for more than a century, it
is only recently that the blood vessel wall was demonstrated as a
reservoir of progenitor cells. We showed that perivascular cells, i.e.
pericytes and adventitial cells, are the in vivo counterpart of MSC
obtained in culture from various organs [21, 22]. Pericytes and
adventitial cells are two perivascular cell compartments with dis-
tinct phenotypes and anatomical locations in situ as well as distin-
guishable behaviours in culture. These perivascular cells can be
prospectively purified by flow cytometry using a well-defined sur-
face marker combination, common in all human organs tested
(Table 1). Importantly, pericytes and adventitial cells dissociated
from vessel wall contain multipotent precursors with robust regen-
eration properties similar to those of classic heterogeneous MSC.
Some studies show that human MSC may accumulate chromo-
somal aberrations [23, 24] in contrast to other reports which
strongly support their chromosomal stability [25, 26].
Our own experiments demonstrated that cultured human peri-
cytes and adventitial cells injected into immunodeficient mice are not
tumorigenic [21].
Table 1 Comparison between human pericytes and adventitial perivascular cells [21, 22]
Pericytes Adventitial cells
Perivascular location Capillaries and microvessels Large vessels
Human tissue origin Adult, foetal and embryonic
skeletal muscle and pancreas,
adult WAT, foetal skin, small intestine,
brain, foetal and embryonic BM, term
and mid-term placenta
Adult WAT, foetal skeletal muscle,
lung and BM
FACS selection CD146+CD34-CD56-CD45- CD34+CD31-CD146-CD45-
Markers in vitro CD146, NG2, PDGFRb, aSMA, CD90,
CD73, CD105, CD44, ALP, nestin, vimentin
CD34, CD90, CD73, CD105, CD44, vimentin
Markers in vivo CD146, NG2, PDGFRb, a SMA,
CD90, CD73, CD105, CD44, ALP
CD34, CD90, CD73, CD105, CD44
Documented
differentiation potential
Osteogenic, adipogenic, chondrogenic,
myogenic
Osteogenic, adipogenic,
chondrogenic, pericytic
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Pericyte characterization
Markers of pericytes
In vivo, the main criterion to identify pericytes remains their ana-
tomical localization and morphology. Beside localization, defining
the molecular phenotype of pericytes has been a challenge. The
3G5 antigen, first suggested to be expressed by pericytes of the
retina and adipose tissue, was later documented as a ubiquitous
pericyte marker [27, 28]. Other pericyte markers have been
described such as the melanoma-associated antigen, Thy1.1, the
ephrin receptor and its ligands, neuropilin-1 and -2 and the Notch
receptor and its ligands, Jagged-1 and Jagged-2. Although none
of these antigens is present exclusively on pericytes [29]. Vimen-
tin and desmin are expressed by most chick pericytes as well as
smooth muscle cells [30]. Alkaline phosphatase (ALP) has been
used to identify and isolate pericytes from adult human skeletal
muscle [31, 32]. The presence of ALP on pericytes from other tis-
sues was next confirmed [21]. Finally, we have demonstrated that
CD146, NG2 and PDGFRb can be used to purify human pericytes
from foetal and adult human tissues [21].
CD146
Perivascular and endothelial cell marker, CD146, aka MUC18, MCAM,
Mel-CAM or S-Endo1, is a transmembrane glycoprotein and a mem-
ber of the immunoglobulin superfamily. Perivascular and endothelial
cell marker, CD146 expression is mainly associated with blood ves-
sels, being present on vascular endothelium, pericytes and smooth
muscle cells [21, 33–35]. In the embryo, CD146 marks other cell
types present in the neural crest, notochord, mesonephros, ectoderm,
somites and skeletal muscle rudiment [36, 37].
However, cells in the paraxial mesoderm do not express CD146
before segmentation; only once somites are specified to the muscle
cell lineage is CD146 expressed. In humans, CD146 expression is
correlated with the development of the trophoblast as early as
12 days post fecundation [14]. The exact role of CD146 is less
obvious. In zebrafish, absence of CD146 inhibits lumen formation in
intersomitic capillaries preventing establishment of the blood flow
and causing defaults in the vascular system [36]. In human adult
BM, CD146 is found on adventitial reticular cells identified as sinu-
soidal pericytes. These osteoprogenitors are able to self renew in
serial transplantation and restore the perivascular cell compartment
[38–40]. In the absence of CD146, no self-renewal has been
observed.
PDGFRb
Platelet-derived growth factor, PDGFRb is expressed on pericytes
[21, 31, 35, 41]. In the absence of PDGFb production by endothelial
cells, pericytes of newborn rats detached from blood vessels [42].
Moreover, mouse embryos deficient in PDGFb and PDGFRb are via-
ble, but die after birth lacking most pericytes and developing haema-
tological, renal and placental abnormalities at late embryonic stages
[43–45]. A compensatory mechanism set to recruit small subsets of
pericytes via the PDGFRa subunit may explain the absence of embry-
onic lethality because complete loss of PDGF signalling is lethal at
embryonic day 9.5 [46].
aSMA and NG2
Alpha smooth muscle actin (aSMA) is a universal marker of smooth
muscle cells in large vessels, as seen in the human umbilical cord at
term (Fig. 1a). Pericytes of microvessels also express aSMA, in con-
trast to most pericytes surrounding capillaries [21, 47, 48]. It is sug-
gested that the presence of aSMA in subsets of pericytes, and
absence from others, is correlated with one of the main functions of
pericytes that is to contract and control blood pressure [49].
The NG2 proteoglycan (neural glial antigen 2), or chondroitin sul-
phate proteoglycan 4, was first described in the nervous system [50]
and later discovered on pericytes and smooth muscle cells [21, 51–
53]. Not all pericytes express NG2, which is circumscribed to the
arterial system [21, 54, 55]. A phenotypic transition from pericytes to
smooth muscle cells has been already proposed [56, 57]. Indeed,
NG2 expression distinguishes three subsets of human pericytes,
associated with: capillaries (NG2+aSMA-), venules (NG2-aSMA+)
and arterioles (NG2+aSMA+) [21, 55]. Interestingly, all three pheno-
types can be seen simultaneously around big vessels such as the
human umbilical cord artery (Fig. 1b), or surrounding large vessels in
the developing human placenta [58]. The human umbilical cord at
term is composed of three large vessels (two veins and one artery)
surrounded by stromal cells and embedded in a mostly acellular sub-
stance named Wharton’s jelly. The mid-gestation umbilical cord con-
tains an additional vein. Pericyte marker, NG2 is not expressed in
either vein of the human umbilical cord, which confirms NG2 as a
marker of arterial/venous polarity. Whereas all perivascular cells
express aSMA within venules, only rare cells within the venular wall
co-express NG2 and aSMA (Fig. 1c). Wharton’s jelly does not contain
NG2-expressing cells (Fig. 1d). In contrast to the human umbilical
cord at term, arteries and veins of the mid-gestation cord do not
show a differential distribution of NG2. Mural cells in all large vessels
co-express NG2 and aSMA, except for the monolayer immediately in
contact with endothelial cells (Fig. 1e). Whether or not the latter can
be named pericytes of large vessels is less obvious although their
presence in adipose tissue was also proposed [59]. Compared to
NG2, CD146 is equally distributed, in the large vessels of the human
term umbilical cord, within the arterial wall and has a distribution
similar to that of NG2 in the vein [60, 61]. In conclusion, our data
define human pericytes as CD146+PDGFRb+CD34-CD56-CD45- cells
(Fig. 2a). Subsets of perivascular cells within this phenotype can be
distinguished by NG2 and aSMA differential expression [21, 55].
Pericyte long-term culture
Because of their implications in pathological processes, tissues such
as the retina, brain, lung, skin and kidney have been used to establish
methods to culture pericytes. These protocols include the growth of
pericytes from microvessels of the bovine retina, a method adapted
to various tissues such as human placenta and adipose tissue [62–
65]. These cultures, albeit enriched in pericytes, remain heteroge-
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neous in term of cell composition. For this reason, we set up to pro-
spectively purify and culture human pericytes (Table 1). When seeded
in culture, purified human pericytes do not attach rapidly, but sit for
several hours then spread on the pre-coated plastic dish and divide
very slowly during the first 2 to 4 passages to eventually proliferate
and expand. Foetal muscle derived pericytes for example can be
expanded up to 40 population doublings [21]. This high capacity to
proliferate is only observed in culture. Indeed, most cultured pericytes
tested at passage 5 express Ki67, in contrast to pericytes in situ, of
which only a few proliferate (Fig. 2b and c). After around 30 dou-
blings, human pericytes grow more slowly and eventually undergo
senescence, similar to conventional MSC [21, 66–68]. In terms of
phenotype, long-term cultured pericytes retain expression of discrimi-
nating markers (CD146, NG2, PDGFRb), and, importantly, exhibit
MSC phenotype and multipotency [21]. Cultured pericytes express
NG2, aSMA, CD44, CD146, PDGFRb and nestin (Fig. 2d–h), but lack
the myogenic and neural cell marker CD56 (Fig. 2i) and the endothe-
lial and haematopoietic cell markers CD34, CD31 and vWF (Fig. 2j–l).
As of morphology, cultured pericytes are large, in general more than
50 lm, with an irregular stellate shape. Pericytes do not show con-
tact inhibition; at confluence, they retract and fuse to eventually form
ball like structures reminiscent of neurospheres. Nestin expressing
mesospheres exhibiting MSC multipotency and myogenic myo-
spheres were similarly isolated from adult murine BM and skeletal
muscle respectively [69–72].
Adventitial cell characterization
Markers of adventitial cells and long-term
culture
The phenotype of progenitors residing in the tunica adventitia of
blood vessels was first described in the mouse. Hu et al. identified a
population of Sca1+ progenitors abundant in the tunica adventitia,
but absent from the tunica media or intima [73]. Upon proper stimu-
lation, purified Sca1+ progenitors differentiated into smooth muscle
cells in vitro and in vivo. The authors also demonstrated that Sca1+
adventitial progenitors actively participate in the formation of athero-
sclerotic lesions by migrating into the tunica media and differentiating
in smooth muscle cells. In agreement with these results Passman
et al. described a population of Sca1+CD34+ckit-CD140b+ progeni-
tors localized in a subregion of the tunica adventitia and highly active
A
B
C D E
Fig. 1 NG2 and aSMA expression in blood
vessels of human umbilical cord (hUC).
Transversal frozen sections of term (a–d)
and mid-term (e) hUC. (a) aSMA (green)
is expressed by perivascular cells (PVC)
and by most of single cells of the Whar-
ton’s jelly (WJ) (b) from lumen to the out-
sider layer, the artery is composed by
blood (BC, blue) and endothelial cells (EC,
blue) NG2-aSMA-, pericytes (PC, red)
NG2+aSMA-, intermediate PVC (IPVC, yel-
low) NG2+aSMA+ and smooth muscle
perivascular cells (SMPVC, green) NG2-
aSMA+. (c) The vascular wall of the vein
mostly expresses aSMA (green). Rare
cells coexpress both NG2 and aSMA
(arrow, yellow). (d) NG2 expression is not
detected in the WJ. (e) the vascular wall
of veins and arteries of the mid-gestation
hUC coexpress NG2 and aSMA (yellow)
except pericytes (PC, red) which are NG2+
aSMA-. All nuclei are stained by DAPI
(blue). Immunostainings were performed
according to our established protocol and
hUC were used according to University of
Pittsburgh regulations [21]. Magnifications:
1009 (a), 2009 (c, d, e) and 4009 (b).
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for sonic hedgehog signalling [74]. Sca1+ adventitial progenitors
were described to retain the potential to differentiate not only into
smooth muscle cells but also into endothelial-like cells and osteo-
blasts, thus confirming that the tunica adventitia represents a niche
for multipotent progenitor cells. Adventitial progenitors with similar
phenotype and potential were also described in humans. Mesenchy-
mal stem cell progenitor, CD34+CD31– cells endowed with the ability
to give rise to endothelial-like cells were detected in the proximity of
the tunica adventitia of adult human thoracic arteries and in the adi-
pose-derived stromal vascular fraction [75–77]. Mesenchymal stem
cell progenitor, CD34+CD31– adventitial cells from the human saphe-
nous vein were shown to associate with endothelial cells in vitro and
in vivo and to promote neo-angiogenesis through paracrine mecha-
nisms [78]. Altogether, these studies indicate CD34+CD31- cells as a
promising cell product for therapeutic angiogenesis, but the potential
of adventitial progenitors is not limited to angiogenesis. A number of
studies have indeed demonstrated that, in mice and in humans, the
tunica adventitia harbours CD34+CD31– mesenchymal stem cell pro-
genitors that may play a role in extravascular tissue homeostasis and
repair [22, 77, 79–81]. We have previously reported pericytes and
adventitial cells as two anatomically and phenotypically distinct popu-
lations of perivascular cells expressing MSC markers in situ and able
to generate MSC-like cells in culture [21, 22]. Mesenchymal stem
cells, MSC generated from pericytes or adventitial cells were undistin-
guishable when assessed for expression of conventional MSC surface
markers (CD90, CD73, CD105, CD44) and ability to differentiate into
bone, fat and cartilage (Table 1). However, similar to murine Sca1+
cells, human adventitia-derived MSC do not express any of the
smooth muscle cell markers aSMA, NG2, CD146 and PDGFRb that
are instead homogeneously expressed by pericyte-derived MSC.
Moreover, adventitial MSC could acquire a pericyte-like phenotype
when stimulated with angiogenic factors [22]. Despite similar mor-
phologies, adventitial cells and pericytes have different abilities to
grow in culture. Differently from pericytes, freshly sorted adventitial
cells rapidly attach and start proliferating in tissue culture plates with-
out the need for gelatin coating. Adventitial cells retain a proliferative
advantage over pericytes over the long term, as showed by a signifi-
cantly lower population doubling time [22]. Clonal cultures can be
grown from both adventitial cells and pericytes [21, 22]. As for other
cell types (haematopoietic cells, endothelial cells), expression of
CD34 is rapidly down-regulated once cells are cultured in vitro, and
CD34 is undetectable after 1 or 2 passages. Finally, similar to peri-
cytes, adventitial cells cultured in a low-attachment plate which main-
tain cells in a suspended, unattached state, can form spheres that
A B C
D E F
G H I
J K L
Fig. 2 Immunofluorescence of human
pericytes before and after long-term cul-
ture. Immunohistochemistry on frozen
section of adult pancreas (a) and foetal
skeletal muscle (b) and immunocytochem-
istry on cultured pericytes (c–l) show the
expression of CD146, NG2, aSMA, CD44,
PDGFRb and nestin by pericytes before
and after culture. Endothelial (vWF, CD34,
CD31) and neural and myogenic (CD56)
markers are absent. Few pericytes express
Ki67, marker of proliferation, in situ (b)
compare to cultured pericytes (c). All
nuclei are stained by DAPI (blue). Pericyte
culture and immunostainings were per-
formed according to our established pro-
tocol and human developing and adult
tissues were used according to University
of Pittsburgh regulations [21]. Magnifica-
tions: 6009 (a); 4009 (b) and 2009
(c–l).
ª 2012 The Authors 2855
Journal of Cellular and Molecular Medicine ª 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 16, No 12, 2012
can be serially passage in vitro. Interestingly, similar CD34+CD31-
spheroidal colonies have been also isolated from pericyte progenitors
of the postnatal rat aorta [82]. Taken together, these studies indicate
the co-existence in situ and in culture of distinct perivascular multipo-
tent progenitors able to contribute to distinct subsets of MSC, possi-
bly organized in a hierarchical fashion. Current studies are aimed to
investigate the contribution of individual or combined pericytes and
adventitial cells to tissue repair.
Adipose tissue is an abundant source of
perivascular MSC
Although pericytes and adventitial cells are ubiquitous multipotent
progenitors, isolation of these cells for clinical purposes is not feasi-
ble from all human tissues. Based on availability, dispensability, har-
vesting procedure and progenitor frequency, human adipose tissue
emerges as an abundant and convenient source of therapeutic peri-
vascular progenitors. Indeed, the adipose stromal vascular fraction
(SVF) is highly enriched in blood vessels and SVF-derived perivascu-
lar cells give rise in vitro to MSC, previously derived indirectly in pri-
mary culture of the unsorted SVF as ADSC (adipose-derived stem
cells) [21]. In 2001, Gronthos et al. demonstrated that ADSC express
all MSC markers: CD105, CD106, CD166, CD44 and importantly the
CD146, perivascular and endothelial cell marker [83]. At the same
time, Zuk et al. demonstrated that ADSC have similar capacity as
MSC to differentiate into adipogenic, osteogenic, chondrogenic and
myogenic cell lineages, at a clonal level [84, 85]. CD146+CD34-
CD31-CD45 –pericytes and CD34+CD146-CD31-CD45– adventitial
cells represent around 15% and 20% of the stromal vascular fraction
respectively [21, 22] whereas perivascular cells in adult bone marrow
are less than 0.5% of total mononuclear cells. Identification of two
frequent multipotent progenitor cell subsets in human adipose tissue
represents a critical step towards the clinical use of autologous stem
cells. Purification and combination of pericytes and adventitial cells
from lipoaspirates would yield clinically relevant numbers of progeni-
tor cells devoid of bystander cells or negative regulators (endothelial
cells), that could be in some indications directly transplanted without
ex vivo expansion. Such an approach would significantly improve the
efficacy and safety of current cell therapy strategies making use of
cultured total stromal cells (James et al., 2012, In press).
Perivascular cells as stem/progenitor
cells for regenerative medicine
Perivascular cells for cardiovascular repair and
regeneration
Despite the multiple roles of pericytes in the pathophysiology of the
cardiovascular system, their application in cardiovascular regenera-
tive medicine remains to be tested. We recently investigated the ther-
apeutic potential of pericytes in ischaemic heart repair. Upon
transplantation into acutely infarcted hearts of NOD/SCID mice,
human muscle-derived and cultured pericytes significantly improved
cardiac function when compared to control injections. Pericytes
exhibited cardio-reparative effects such as promotion of angiogene-
sis, reduction of scar and inhibition of chronic inflammation, likely
because of their secretion of a variety of trophic factors (Chen et al.,
submitted). Dar et al. very recently described the production of peri-
cytes from spontaneously differentiating embryoid bodies derived
from human pluripotent stem cells (hPSC) [86]. These CD105+CD90
+CD73+CD31- multipotent mesodermal precursors express the peri-
cyte markers CD146, NG2 and PDGFRb but not the smooth muscle
cell marker, aSMA. hPSC-derived pericytes transplanted into immu-
nodeficient mice with ligature induced limb ischaemia not only
induced vascular regeneration but also promoted muscle repair, by
incorporating into the damaged muscle and vasculature [86]. Peri-
cytes have been also used to engineer vascular grafts: a cylindrical
synthetic scaffold seeded with human muscle pericytes and trans-
planted into the sectioned rat aorta supported the development of a
structurally and functionally normal blood vessel [87]. These results
suggest that pericytes can serve as a cell source for cardiovascular
therapy. The use of adventitial cells in cardiovascular repair and
regeneration has been also investigated. Campagnolo et al. showed
that CD34+CD31- adventitial cells interact with endothelial cells and
promote the formation and stabilization of capillary-like structures. A
significant pro-angiogenic effect of adventitial cells was observed
after administration in mouse ischaemic limbs, as shown by full
recovery of blood flow as early as 7 days post treatment.
These results indicate the therapeutic capacity of adventitial cells
in post injury angiogenesis/vasculogenesis [78]. Very recently, the
same group reported that transplantation of adventitial cells improves
repair of the mouse infarcted heart through angiogenesis involving
microRNA-132 (miR-132). Adventitial cells treatment enhanced car-
diac repair in multiple aspects, augmenting cardiac contractility,
attenuating LV dilatation, reducing cardiomyocyte apoptosis and
interstitial fibrosis, increasing myocardial blood flow and neovascular-
ization and decreasing vascular permeability. The paracrine function
of adventitial cells activates endogenous repair responses, including
pro-angiogenic and pro-survival Akt/eNOS/Bcl-2 signalling. Further-
more, adventitial cells constitutively express and secrete miR-132
and markedly up-regulate its expression upon stimulation, which in
turn acts as a paracrine activator of cardiac healing [88]. Together
these data indicate the therapeutic potential of pericytes and adventi-
tial cells in ischaemic tissue repair.
Perivascular cells for the regeneration of other
tissues
The effect of pericytes on muscle regeneration was examined in
immunodeficient mouse models of skeletal muscle injury and dystro-
phy [21]. Pericytes (CD146+CD34-CD45-CD56-) purified using flow
cytometry from human skeletal muscle biopsies were injected into
the hind-limb muscles of SCID-non-obese diabetic (NOD/SCID) mice
after injury by intramuscular injection of cardiotoxin. Pericyte-derived
muscle fibres were detected by the presence of human-specific spec-
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trin and centrally located human nuclei [21]. Both freshly sorted and
long-term cultured pericytes generated more human myofibres than
human CD56+ skeletal myoblasts and total unsorted muscle cells.
This ruled out the possibility that the myogenic potential observed in
pericytes results from a contamination by myoblasts in culture. Inter-
estingly, myogenic potential also exists in pericytes residing in other
human organs, including placenta, white adipose tissue and pan-
creas.
Pericytes purified from those non-muscular organs not only
exhibited myogenic potential in culture but also regenerated human
dystrophin- or spectrin-positive myofibres upon injection into mdx/
SCID or cardiotoxin-treated NOD/SCID mouse muscles, in which they
also promoted angiogenesis [21, 64]. These results confirmed that
pericytes sorted from healthy and dystrophic human skeletal muscle
biopsies by ALP expression regenerate human myofibres in the mus-
cles of dystrophic immunodeficient mice [31]. Lately, using a trans-
genic labelling of alkaline phosphatase in the cre/lox inducible
expression system, the same group demonstrated that pericytes
residing in the postnatal skeletal muscle naturally participate in the
regeneration of the injured/dystrophic skeletal muscle [32]. New
results further suggest a connection between muscle-residing peri-
cytes and NF-jB activation in human muscle regenerative response
following eccentric contractions [89]. These results document the
role of pericytes in muscle regeneration and suggest their future
applications in skeletal muscle therapy. Human pericytes can also
make bone. When cultured in standard osteogenic medium, pericytes
exhibited alkaline phosphatase expression and mineral deposition.
Pericytes seeded onto Gelfoam scaffolds and implanted into skeletal
muscle pockets in immunodeficient mice developed into bony nod-
ules [21]. Furthermore, when cultured in the presence of an osteoin-
ductive growth factor, Nell-1, pericytes exhibited robust osteogenic
differentiation on either culture plastic ware or human cancellous
bone chip (hCBC) scaffold. Upon implantation into a muscle pouch in
the nude mouse, pericytes seeded on hCBC formed significantly more
new bone than hCBC scaffold alone. Nell-1 significantly increased
pericyte proliferation as well as osteogenic differentiation in vitro and
in vivo [90]. These and other more recent results suggest pericytes
as novel therapeutic cells for skeletal regenerative medicine (James
et al. 2012, In press). Overall, the superior regenerative capacity of
pericytes can be attributed to multiple factors, including intrinsic mul-
tilineage developmental potential, robust paracrine function and effi-
cient migration in response to stimuli [21, 60, 64, 91–93].
We and others have demonstrated that adventitial cells, regard-
less of their tissue of origin also display developmental features
typical of MSC [17, 22, 73, 78, 79, 88, 94]. Although myogenic
potential remains to be determined, the ability of adventitial cells
to differentiate into major mesodermal cell lineages, including
bone and cartilage, suggests a contribution of these cells in
mesodermal organ development and post injury regeneration. Alto-
gether, these reports suggest that beyond a mere structural con-
stituent of the vascular wall, the adventitia is a dynamic reservoir
of stem/progenitor cells that participate in vascular remodelling
and regeneration of surrounding tissues.
Conclusion
Mesenchymal stem cells are one of the most promising stem/pro-
genitor cell populations for regenerative medicine. Despite this
potential, MSC are heterogeneous and their origin in situ has long
remained unknown. We and others recently demonstrated that two
main types of perivascular cells, pericytes and adventitial cells, are
the native counterparts of MSC in developing and adult human
organs. Studies on prospectively purified subsets of MSC will
reveal important facts regarding their stemness, developmental
biology, migratory capacity and regenerative potential. This will
provide a better understanding of perivascular/MSC behaviour in
health and disease and allow their optimal utilization in regenera-
tive medicine.
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